Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vertex Pharmaceuticals (VRTX) -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (724)	10/5/2005 12:24:36 PM
From: rkrw	Read Replies (2) \| Respond to of 1169

This was a typical case in point of what I was talking about. MMPD, something Boger had latched onto as a core piece of their hcv franchise, is now being scrapped. Which was very easy to predict. Filtering out weak candidates is a process vrtx should have been doing from day one. vrtx suffered from a common biotech syndrome of never wanting to kill weak programs, allowing them to claim they'd never killed a program :-) 950 is a tremendous prospect, defining for vrtx and a true potential breakthrough product. map kinase is high risk stuff.